ARQT - Arcutis stock rallies 28% in wake of FDA approval for dermatology drug
2023-12-18 10:39:54 ET
More on Arcutis Biotherapeutics
- Arcutis Biotherapeutics: Almost There, But Needs Some Fine-Tuning
- Arcutis Biotherapeutics, Inc. (ARQT) Q3 2023 Earnings Call Transcript
- Arcutis Biotherapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation
- Arcutis shares rally in after-hours trading on FDA approval
- Arcutis lead product undergoes FDA review for label expansion
For further details see:
Arcutis stock rallies 28% in wake of FDA approval for dermatology drug